Primary immunodeficiency patients in published studies of virus-specific T-cell therapy
| Study . | Target . | VST manufacturing method . | Source . | No. of PID patients treated . | Results . | AEs . |
|---|---|---|---|---|---|---|
| Uhlin et al23 | CMV | Selection (A02:01 pp65/NLV pentamer) | Third party | 1 | PR, died after subsequent UCBT transplant | None |
| Bao et al30 | CMV | Culture, peptide | HSCT donor | 4 | CR in 2, PR in 1, NR in 1 | None |
| Creidy et al31 | CMV/Adv | Selection by IFN-γ secretion | HSCT donor | 5 | CR in 2, NR in 3 with death due to viral progression in 2 | DAH in 1, no GVHD |
| Feucht et al42 | Adv | Selection by IFN-γ secretion | HSCT donor | 1 | CR | None |
| Feuchtinger et al22 | Adv | Selection by IFN-γ secretion | HSCT donor | 7 | Responses in 21/30 patients overall (18 CR, 4 PR). No specific details regarding subjects with PID. | None |
| Leen et al17 | CMV, EBV, Adv | Culture, DC/LCL with Ad5f35-CMVpp65 vector | HSCT donor | 1 | CR (Adv) | None |
| Leen et al35 | EBV, Adv | Culture, DC/LCL with Ad5f35 vector | HSCT donor | 1 | Prophylactically treated; no subsequent viral infections | None |
| Papadopoulou et al20 | CMV, EBV, Adv, HHV6, BKV | Culture, peptide | HSCT donor | 4 | CR in 3, 1 patient with CR to HHV6 and EBV but NR to BKV | De novo grade 2 skin GVHD in 1 patient, resolved with topical therapy |
| Vickers et al, Wynn et al36,37 | EBV | Culture, LCL | Third party | 3 | CR in 1, progressive disease in 2 | GVHD grade 2 skin in 1 |
| Heslop et al38 | EBV | Culture, LCL | HSCT donor | 14 | CR in 4, PR in 3, NR in 1, 5 treated prophylactically without reactivation | None |
| Doubrovina et al19 | EBV | Culture, LCL | HSCT donor or third party | 3 | CR in 1 (third party), NR in 2 | None |
| Naik et al43 | CMV, EBV, Adv | Culture (LCL, peptide, or viral vector) | HSCT donor or third party | 13 (newly reported) | CR in 6, PR in 3, NR in 2, 2 free of viral infections | aGVHD in 3 (grade 2-3), cGVHD in 1 (grade 1) |
| Miller et al39 | Adv | Culture, peptide | Third party | 1 | CR | None |
| Punwani et al40 | CMV | Culture, peptide | HSCT donor | 1 | CR | None |
| Withers et al28 | CMV, EBV, Adv | Culture, peptide | Third-party | 4 | CR in 3, NR in 1 | None |
| Gerdemann et al34 | CMV, EBV, Adv | Culture, plasmid nucleofection | HSCT donor | 1 | CR | None |
| Tzannou et al29 | CMV, EBV, Adv, HHV6, BKV | Culture, peptide | Third party | 2 | CR (Adv) in 2, PR (CMV) in 1 | Flare of preexisting GI GVHD in 1 (in setting of IS wean); resolved with therapy |
| Abraham et al41 | CMV, EBV, Adv | Culture (DC, LCL with Ad5f35-pp65 or peptide) | HSCT donor (UCBT) | 3 | All free of viral infection | None |
| Tzannou et al44 | CMV | Culture, peptide | Third party | 2 | CR in 2 | None |
| Study . | Target . | VST manufacturing method . | Source . | No. of PID patients treated . | Results . | AEs . |
|---|---|---|---|---|---|---|
| Uhlin et al23 | CMV | Selection (A02:01 pp65/NLV pentamer) | Third party | 1 | PR, died after subsequent UCBT transplant | None |
| Bao et al30 | CMV | Culture, peptide | HSCT donor | 4 | CR in 2, PR in 1, NR in 1 | None |
| Creidy et al31 | CMV/Adv | Selection by IFN-γ secretion | HSCT donor | 5 | CR in 2, NR in 3 with death due to viral progression in 2 | DAH in 1, no GVHD |
| Feucht et al42 | Adv | Selection by IFN-γ secretion | HSCT donor | 1 | CR | None |
| Feuchtinger et al22 | Adv | Selection by IFN-γ secretion | HSCT donor | 7 | Responses in 21/30 patients overall (18 CR, 4 PR). No specific details regarding subjects with PID. | None |
| Leen et al17 | CMV, EBV, Adv | Culture, DC/LCL with Ad5f35-CMVpp65 vector | HSCT donor | 1 | CR (Adv) | None |
| Leen et al35 | EBV, Adv | Culture, DC/LCL with Ad5f35 vector | HSCT donor | 1 | Prophylactically treated; no subsequent viral infections | None |
| Papadopoulou et al20 | CMV, EBV, Adv, HHV6, BKV | Culture, peptide | HSCT donor | 4 | CR in 3, 1 patient with CR to HHV6 and EBV but NR to BKV | De novo grade 2 skin GVHD in 1 patient, resolved with topical therapy |
| Vickers et al, Wynn et al36,37 | EBV | Culture, LCL | Third party | 3 | CR in 1, progressive disease in 2 | GVHD grade 2 skin in 1 |
| Heslop et al38 | EBV | Culture, LCL | HSCT donor | 14 | CR in 4, PR in 3, NR in 1, 5 treated prophylactically without reactivation | None |
| Doubrovina et al19 | EBV | Culture, LCL | HSCT donor or third party | 3 | CR in 1 (third party), NR in 2 | None |
| Naik et al43 | CMV, EBV, Adv | Culture (LCL, peptide, or viral vector) | HSCT donor or third party | 13 (newly reported) | CR in 6, PR in 3, NR in 2, 2 free of viral infections | aGVHD in 3 (grade 2-3), cGVHD in 1 (grade 1) |
| Miller et al39 | Adv | Culture, peptide | Third party | 1 | CR | None |
| Punwani et al40 | CMV | Culture, peptide | HSCT donor | 1 | CR | None |
| Withers et al28 | CMV, EBV, Adv | Culture, peptide | Third-party | 4 | CR in 3, NR in 1 | None |
| Gerdemann et al34 | CMV, EBV, Adv | Culture, plasmid nucleofection | HSCT donor | 1 | CR | None |
| Tzannou et al29 | CMV, EBV, Adv, HHV6, BKV | Culture, peptide | Third party | 2 | CR (Adv) in 2, PR (CMV) in 1 | Flare of preexisting GI GVHD in 1 (in setting of IS wean); resolved with therapy |
| Abraham et al41 | CMV, EBV, Adv | Culture (DC, LCL with Ad5f35-pp65 or peptide) | HSCT donor (UCBT) | 3 | All free of viral infection | None |
| Tzannou et al44 | CMV | Culture, peptide | Third party | 2 | CR in 2 | None |
Adv, adenovirus; AE, adverse event; aGVHD, acute GVHD; cGVHD, chronic GVHD; DAH, diffuse alveolar hemorrhage; DC, dendritic cell; IS, immunosuppression; LCL, lymphoblastoid cell line; UCBT, umbilical cord blood transplant.